 |
Европейская академия
|
| В начало | Энциклопедия ЕАЕН | |
Энциклопедия Европейской академии естественных наук |
||
Qian Qijun
Qian Qijun, Ph.D., Professor. He currently serves as the Vice Dean of the Medical School at Shanghai University, the President of the Shanghai University Institute for Cell Therapy Innovation, the President of the Shanghai Institute for Cell Therapy, the Director of the Shanghai Engineering Research Center for Cell Therapy, the Director of the Shanghai Wu Mengchao Joint Nobel Laureate Medical Science and Technology Innovation Center, and the Chairman and President of the Shanghai Cell Therapy Group.
He is a recipient of the National Science Fund for Distinguished Young Scholars, the Chief Scientist of the National Key Research and Development Program's Precision Medicine Initiative, a leading academic figure in Shanghai, a leading talent in Shanghai, and a recipient of the Shanghai May Day Labor Medal. He currently serves as the Vice Chairman of eight industry associations, including the Precision Medicine Branch of the China Biomedical Technology Association and the Cell Therapy Quality Control and Research Committee of the China Association for Pharmaceutical Quality Management.
He has presided over 16 national-level projects, including major national science and technology projects, the 863 Program, projects for distinguished young scholars by the National Natural Science Foundation of China, projects for overseas distinguished young scholars, major projects, key projects, and general projects. He has received one national scientific and technological progress innovation team award, four second-class awards at the provincial and ministerial levels, and three third-class awards. He has published 83 SCI papers and has applied for 217 patents related to cell therapy, of which 47 have been granted, including two U.S. invention patents.
His main research interests are in precision tumor cell immunotherapy, including clinical application of precision cell immunotherapy, research and development of new precision cell immunotherapy technologies, precision immune cell storage, genetic testing, clinical-scale preparation of precision cells, and the development of related equipment. His team is currently developing new cell therapies named "Xuan Tie Sword," which involves gene modification using non-viral vectors to create a new generation of CAR-T cells; "Liu Mai Shen Jian," which precisely targets and kills cancer cells using PNA-T; and "Yi Tian Sword," which aims to alter the cancer microenvironment and lift the suppression on immune cells by expressing immune checkpoint antibodies such as anti-PD-1, using non-viral vectors, nanobodies, and mRNA technology to realize the integrated Bai Ze Sword technique and the super Bai Ze T cells. In April 2019, his project targeting CD19 with CAR-T cell therapy was granted permission by the National Medical Products Administration to conduct clinical trials, making it the first in China to enter clinical trials with a non-viral vector-prepared CAR-T cell therapy product. He is one of the earliest researchers to propose a new strategy for cancer gene-virus therapy, which combines the dual advantages of traditional cancer gene therapy and virus therapy. In vitro and in vivo experiments have demonstrated the superior efficacy of this strategy over gene therapy or virus therapy alone. Based on this, he has developed an adenovirus production and purification platform, providing adenovirus technical support to hundreds of domestic institutions. He was the first to successfully use an adenovirus vector system to efficiently express full-length antibodies and was the first internationally to propose a full-length antibody gene therapy strategy.
| Энциклопедия ЕАЕН |